Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

This study has been terminated.
(Futility)
Sponsor:
Information provided by:
Neurobiological Technologies
ClinicalTrials.gov Identifier:
NCT00141011
First received: August 30, 2005
Last updated: December 21, 2009
Last verified: December 2009
  Purpose

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.


Condition Intervention Phase
Stroke
Cerebral Ischemia
Brain Infarction
Drug: Ancrod (Viprinex)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke

Resource links provided by NLM:


Further study details as provided by Neurobiological Technologies:

Primary Outcome Measures:
  • Responder analysis based on Modified Rankin Scale (mRS) [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • National Institute of Health Stroke Scale (NIHSS),Barthel Index (BI),Fibrinogen levels with ancrod tx, and Safety of ancrod tx [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Enrollment: 277
Study Start Date: September 2005
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous ancrod
Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
Drug: Ancrod (Viprinex)
0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
Placebo Comparator: Intravenous Placebo
Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
Drug: Placebo
0.6 mL/kg/hr

Detailed Description:

With prior approval by the FDA, an interim analysis for futility was performed when 500 subjects had been entered into the two parallel trials, NCT00141001 and NCT00300196. The analyses were reviewed by the data safety monitoring board, which recommended that both studies be terminated because of futility. This was done at a point where 650 subjects had been entered into both studies, combined, but analyses were conducted only on the initial 500 subjects. Results of the abbreviated analysis will be found with study NCT00141001 since that study contributed most of the subjects to the analysis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment
  • Baseline NIHSS > 5

Exclusion Criteria:

  • No intracranial, extravascular blood on CT
  • Hypertension (systolic > 185; diastolic > 105)
  • Baseline fibrinogen level < 100 mg/dL
  • Thrombocytopenia (< 100,000 / mm3)
  • Recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent
  • Recent (< 14 days) or anticipated surgery
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00141011

  Hide Study Locations
Locations
United States, Arizona
Mayo Clinic Hospital / Arizona
Phoenix, Arizona, United States, 85054
United States, Arkansas
Sparks Regional Medical Center
Fort Smith, Arkansas, United States, 72901
United States, California
Loma Linda University School of Medicine
Loma Linda, California, United States, 92354
UCLA Medical Center
Los Angeles, California, United States, 90024
Santa Monica - UCLA Medical Center
Los Angeles, California, United States, 90024
Hoag Memorial Hospital
Newport Beach, California, United States, 92658
The Neurology Center: Tri-City Medical Center
Oceanside, California, United States, 92056
Shasta Regional Medical
Redding, California, United States, 96001
United States, Connecticut
Bridgeport Hospital
Bridgeport, Connecticut, United States, 06610
United States, Florida
Neurologic Consultants, P.A.
Fort Lauderdale, Florida, United States, 33308
Shands Jacksonville / University of Florida
Jacksonville, Florida, United States, 32209
Ocala Neurodiagnostic Center
Ocala, Florida, United States, 34471
Florida Hospital Neuroloscience Institute
Orlando, Florida, United States, 32804
Fawcett Memorial Hospital
Port Charlotte, Florida, United States, 33952
Peace River Regional Medical Center
Port Charlotte, Florida, United States, 33952
Tallahassee Memorial Healthcare, Inc.
Tallahassee, Florida, United States, 32303
United States, Hawaii
The Queens Medical Center, Neuroscience Institute
Honolulu, Hawaii, United States, 96813
United States, Illinois
Mercy Hospital
Chicago, Illinois, United States, 60616
United States, Indiana
Elkhart Clinic, LLC - Neurology
Elkhart, Indiana, United States, 46514
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States, 46804
Parkview Research Center
Fort Wayne, Indiana, United States, 46805
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, Massachusetts
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
United States, Minnesota
St. Mary's Duluth Clinic
Duluth, Minnesota, United States, 55805
Minneapolis Clinic of Neurology
Golden Valley, Minnesota, United States, 55422
United States, Montana
Deaconess Billings Clinical Research Center
Billings, Montana, United States, 59101
United States, New Jersey
NJ Neuroscience Institute
Edison, New Jersey, United States, 08818
Neurology Consultants Of Burlington County
Lumberton, New Jersey, United States, 08048
UMDNJ / Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08901
Neurology Group of Bergen County
Ridgewood, New Jersey, United States, 07450
Shore Neurology
Toms River, New Jersey, United States, 08755
United States, New York
Kaleida Stroke Center
Buffalo, New York, United States, 14209
United Health Services Hospitals
Johnson City, New York, United States, 13790
Winthrop University Hospital
Minneola, New York, United States, 11501
Weill Medical College of Cornell University
New York, New York, United States, 10021
Strong Memorial Hospital
Rochester, New York, United States, 14642
Rochester General Hospital
Rochester, New York, United States, 14621
United States, North Carolina
Presbyterian Hospital
Charlotte, North Carolina, United States, 28204
Lebauer Cardiovascular Research Foundation at Moses Cone Hospital
Greensboro, North Carolina, United States, 27401
Clinical Research of Winston-Salem
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
The Toledo Hospital
Toledo, Ohio, United States, 43606
Medical University of Ohio
Toledo, Ohio, United States, 43614
United States, Pennsylvania
Northshore Clinical Associates
Erie, Pennsylvania, United States, 16507
Westmoreland Neurology Associates, Inc.
Greensburg, Pennsylvania, United States, 15601
United States, Rhode Island
Miriam Hospital
Providence, Rhode Island, United States, 02906
United States, South Carolina
Beaufort Memorial Hospital
Beaufort, South Carolina, United States, 34205
United States, Tennessee
Methodist University Hospital
Memphis, Tennessee, United States, 38104
United States, Texas
Brackenridge Hospital
Austin, Texas, United States, 78701
Seton Medical Center
Austin, Texas, United States, 78705
Methodist Hospital / Neurological Institute
Houston, Texas, United States, 77030
University of Texas Health Sciences Center
San Antonio, Texas, United States, 78229
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23219
Neurological Consultants of Virginia Beach
Virginia Beach, Virginia, United States, 23454
United States, Washington
Harborview Medical Center
Seattle, Washington, United States, 98104
Madigan Army Medical Center
Tacoma, Washington, United States, 98431
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
St. Lukes Medical Center
Milwaukee, Wisconsin, United States, 53215
Australia, New South Wales
Gosford Hospital Department of Neurology
Gosford, New South Wales, Australia, 2250
Australia, South Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Box Hill Hospital
Box Hill, Victoria, Australia
National Stroke Research Institute
Heidelberg Heights, Victoria, Australia, 3081
Canada, Alberta
Grey Nuns Community Hospital
Edmonton, Alberta, Canada, 1100
Canada, Newfoundland and Labrador
Western Memorial Health Clinic
Corner Brook, Newfoundland and Labrador, Canada, A2H 4B8
Canada, Ontario
London Health Sciences Centre - University Hospital
London, Ontario, Canada
Trillum Health Centre
Mississauga, Ontario, Canada, L5B1B8
Canada, Quebec
Hospital Charles-Leymoyne
Greenfield Park, Quebec, Canada, J4V2h1
Canada
University of Alberta Hospital
Edmonton, Canada, T6G2B7
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Canada, P7B7C7
Czech Republic
St. Anne's Faculty Hospital
Brno, Czech Republic, 65691
Faculty Hospital 1, The Clinic of Neurology
Pilsen, Czech Republic, 30460
Netherlands
St. Anna Hospital
Geldrop, Netherlands, 5660 AB
Poland
University Clinical Hospital
Warsaw, Poland, 02-097
Russian Federation
City Hospital #31
Moscow, Russian Federation, 119415
Research Institute of Neurology RAMS
Moscow, Russian Federation, 125367
Military Medical Akademy Dept of Neurology
St. Petersburg, Russian Federation, 194044
South Africa
St. Augustine's Hospital
Berea, Durban, Kwazulu Natal, South Africa, 4001
Tiervlei Trial Centre
Cape Town, South Africa, 7536
Vergelegen Medi-Clinic
Somerset West, South Africa, 7130
Sunninghill Hospital
Sunninghill, South Africa, 2157
Taiwan
Changhua Christian Hospital, Chief Department of Neurology
Changhua, Taiwan, 50022
Lo-Tung Pohai Hospital, Department of Neurology
IIan, Taiwan, 265
Kaohsiung Chang-Gung, Memorial Hospital
Kaohsiung, Taiwan, 83305
Chung-Ho Memorial Hospital Kaohsiung Medical University
Kaohsiung, Taiwan, 807
China Medical University Hospital
Taichung, Taiwan, 404
Chung Shan Medical Hospital
Taichung, Taiwan, 402
Kuang-Tien General Hospital
Taichung, Taiwan, 433
Taichung Veterans General Hospital, Section of Neurology
Taichung, Taiwan, 407
Chi-Mei Medical Center
Tainan, Taiwan, 710
Far Eastern Memorial Hospital
Taipei, Taiwan, 220
Tri-Service General Hospital
Taipei, Taiwan, 114
Shin-Kong WHS Memorial Hospital
Taipei, Taiwan, 111
En Chu Kong Hospital
Taipei, Taiwan, 23702
Cathay General Hospital Department of Neurology
Taipei City, Taiwan, 11073
National Taiwan University Hospital
Taipei City, Taiwan, 100
Chang-Gung Memorial Hospital, Linko Medical Center
Taoyuang, Taiwan, 333
Chang-Gung Memorial Hospital Linko Medical Center
Taoyuang, Taiwan, 333
United Kingdom
University of Aberdeen, Polwarth Building, Institute of Medical Sciences, Dept. of Medicine & Theropeutics
Aberdeen, United Kingdom, AB252ZD
Institute of Neurological Sciences Southern General Hospital
Glasgow, United Kingdom, G514TF
Royal Victoria Infirmary - Clinical Research Center
New Castle, United Kingdom
Sponsors and Collaborators
Neurobiological Technologies
Investigators
Study Director: Warren Wasiewski, M.D. Neurobiological Technologies
  More Information

Additional Information:
No publications provided

Responsible Party: Warren W. Wasiewski, M.D., Neurobiological Technologies, Inc.
ClinicalTrials.gov Identifier: NCT00141011     History of Changes
Other Study ID Numbers: NTI-ASP-0502
Study First Received: August 30, 2005
Last Updated: December 21, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Neurobiological Technologies:
Stroke
Fibrinogen
Reperfusion
Thrombolysis

Additional relevant MeSH terms:
Cerebral Infarction
Brain Ischemia
Infarction
Ischemia
Stroke
Brain Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Necrosis
Ancrod
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on June 13, 2013